Treating endometriosis as an autoimmune disease

Fertility and Sterility

Volumn 76, Issue 2, 2001, Pages 223-231

  Nothnick, Warren B ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Autoimmune disease; Cytokines; Endometriosis; Immunomodulators; Inflammation; Medical therapy

Indexed keywords

ANTIGESTAGEN; BUSERELIN; CYTOKINE; DANAZOL; ESTROGEN; ETANERCEPT; GONADORELIN DERIVATIVE; GOSERELIN; IMMUNOMODULATING AGENT; INFLIXIMAB; LEFLUNOMIDE; LEUPRORELIN; METHOTREXATE; NAFARELIN; PENTOXIFYLLINE; PROGESTERONE; STEROID; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CROHN DISEASE; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0034888634     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)01878-7     Document Type: Review

References (100)

1. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity
2. Retrograde seeding of endometrium: Sequelia of tubal flushing
3. Endometrial tissue in peritoneal fluid
4. The viability of cast-off menstrual endometrium
5. Cell with mucous membrane of the female genital tract in culture: A comparative study with regard to the histogenesis of endometriosis
6. Experimental endometriosis
7. Experimental endometriosis in the human
8. Endometriosis: Pathogenic implications of the anatomic distribution
9. Retrograde menstruation in healthy women and in patients with endometriosis
10. Endometriosis: Its association with retrograde menstruation, dysmenorrhea, and tubal pathology
11. Deeply infiltrating endometriosis is a disease whereas mild endometriosis could be considered a nondisease
12. Deficient cellular immunity in endometriosis
13. Immunologic aspects of human endometriosis
14. Immune rosettes of T and B lymphocytes in infertile women with endometriosis
15. Lymphocyte subsets in endometriosis
16. Characterization of leukocyte subpopulations in the peritoneal fluid of women with endometriosis
17. The role of cell-mediated immunity in pathogenesis of endometriosis
18. Characterization of lymphocyte subpopulations and T cell activation ind endometriosis
19. Lymphocyte subsets in the endometrium of patients with endometriosis throughout the menstrual cycle
20. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium
21. Decreased natural killer cell activity in endometriosis patients: Relationship to disease pathogenesis
22. Peritoneal natural killer cytotoxicity and CD25+CD3+ lymphocyte subpopulation are decreased in women with stage III-IV endometriosis
23. Immunomodulation in women with endometriosis receiving GnRH agonist
24. Suppression of natural killer cell activity by sera from patients with endometriosis
25. Immunosuppressive activity of peritoneal fluid in women with endometriosis
26. Enhancement of human monocyte and peritoneal macrophage chemiluminescence activities in women with endometriosis
27. Peritoneal fluid cell populations in infertility patients
28. Pelvic macrophages in normal and infertile women: The role of patent tubes
29. Accentuated cyclic activation of peritoneal macrophages in patients with endometriosis
30. Altered maturation and function of peritoneal macrophages: Possible role in the pathogenesis of endometriosis
31. Functional aspects of peritoneal macrophages in endometriosis of women
32. The effect of growth factors on the proliferation of human endometrial stromal cells in culture
33. Tumor necrosis factor-α promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression
34. Effect of TNF-α on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: An in vitro system
35. Paracrine regulation of matrix metalloproteinase expression in the normal endometrium
36. Angiogenesis and macrophage activation in endometriosis
37. Clinical immunological aspects of genital endometriosis
38. Endometriosis: Can it produce an autoimmune response resulting in infertility?
39. Autoimmunity to endometrium and ovary in endometriosis
40. Is endometriosis an autoimmune disease?
41. Autoimmunity in infertility patients with endometriosis
42. Are there antiendometrial antibodies in sera of women with endometriosis?
43. Autoreactivity in women with endometriosis
44. Markers for endometriosis
45. Endometrial antibodies in serum and peritoneal fluid of infertile patients with and without endometriosis
46. Localization of anti-endometrial antibody binding in women with endometriosis using a double-labelling immunohistochemical method
47. Antiendometrial antibodies in patients with endometriosis
48. Endometriosis and infertility
49. Danazol but not gonadotropin-releasing hormone agonists suppress autoantibodies in endometriosis
50. Antiendometrial antibodies in endometriosis measured by an enzyme-linked, immunosorbent assay before and after treatment with danazaol and nafarelin
51. The peritoneal environmental in endometriosis
52. Integrin-mediated adhesion of uterine endometrial cells from endometriosis patients to extracellular matrix proteins is enhanced by tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1)
53. Whole explants of peritoneum and endometrium: A novel model of the early endometriosis lesion
54. Expression of the α2β1 and α3β1 integrins at the surface of mesothelial cells: A potential attachment site of endometrial cells
55. Invasiveness of endometriotic cells in vitro
56. Early endometriosis invades the extracellular matrix
57. Deeply infiltrating pelvic endometriosis: Histology and clinical significance
58. Expression of MMP-3 and TIMP-1 in endometriosis and the influence of danazol
59. Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis
60. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human tissue in nude mice
61. Apoptosis and autoimmune disease
62. Gonadotropin-releasing hormone analog repairs reduced endometrial cell apoptosis in endometriosis in vitro
63. Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis
64. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis
65. Rheumatoid arthritis: New disease-modifying and anti-inflammatory drugs
66. Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts
67. Matrix metalloproteinase production by cultured human endometrial stromal cells: Identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha
68. Mast cell regulation of human endometrial matrix metalloproteinases: A mechanism underlying menstruation
69. Medical treatment of endometriosis
70. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy
71. Progesterone-induced immunosuppression is not mediated through the progesterone receptor
72. Immunosuppressive effects of danazol in vitro
73. Danazol suppresses the production of interleukin-1β and tumor necrosis factor by human monocytes
74. Effect of danazol on the immunocompetent cells in the eutopic endometrium in patients with endometriosis: A multicenter cooperative study
75. The suppression of peritoneal cellular immunity in women with endometriosis could be restored after gonadotropin releasing hormone agonist treatment
76. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro
77. Role of cytokines in progression of endometriosis
78. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium
79. Gene expression of gonadotropin-releasing hormone, but not its receptor in human endometrium and decidua
80. Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate
81. Long-term gonadotropin-releasing hormone agonist therapy: The evolving issue of steroidal 'add-back' paradigms
82. Should add-back therapy for endometriosis be deferred for optimal results?
83. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women
84. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: A multicenter, double-blind randomized clinical trial. II. Assessment of safety
85. Depressive symptoms associated with gonadotropin-releasing hormone agonists
86. Lupron-induced mania
87. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: A paradigm for a novel approach to the treatment of endometriosis-associated subfertility
88. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: A pilot randomized clinical trial
89. Immunomodulation of rat endometriotic implant growth and protein production
90. How to treat endometriosis-associated subfertility. Or should we?
91. Immune dysfunction - A potential target for treatment in endometriosis
92. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
93. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis
94. In vitro effects of pentoxifylline on inflammatory cytokine release in patients with inflammatory bowel disease
95. Cellular and molecular regulation of tumor necrosis factor-alpha by pentoxifylline
96. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline
97. Mechanism of action for leflunomide in rheumatoid arthritis
98. Etanercept: A review of its use in rheumatoid arthritis
99. Infliximab: A review of its use in the management of rheumatoid arthritis